EDGAR·FLOW

Longeveron Inc. — Form 8-K

Filed November 12, 2026 · analyzed by the 8-K Agent
8-K ▼ Likely negative significance 78/100
What the filing says
Longeveron's ELPIS II Phase 2b trial missed its primary efficacy endpoint for laromestrocel in hypoplastic left heart syndrome (40 infants), though showed fewer adverse events in secondary analysis (1 MACE event vs. 8 in standard of care arm, P=0.043). The company has requested an FDA meeting to determine next steps. Concurrently, it initiated a formal strategic review process (retaining Lucid Capital Markets as financial advisor) to explore partnerships, financing, sales, or mergers to maximize shareholder value; implemented cash conservation measures; and reported Q3 2026 net loss of $6.1M on $115K revenue, with $7.2M cash (funding into Q1 2027). A 1-for-10 reverse stock split occurred on August 26, 2026.
Why this rating

Failed primary endpoint on lead program is materially adverse for a $16.5M clinical-stage biotech; strategic review + cash runway pressure are existential concerns. Relative to company size, this is trajectory-threatening.

Tradability signal
NO TRADE

No trade: negative news, but this cell's evidence is too weak. Similar past filings (324 in this cell) moved -1.31% in the called direction over 4 hrs; shrunk for sample size that's a -1.22% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it negative)
before filing · preread
$2.97 ▲ 6.26%
at our read · unknown
$2.79
+10 min · unknown
$2.88 ▲ 3.04%
+30 min · unknown
$2.61 ▼ 6.62%
+1 hr · unknown
$2.48 ▼ 11.45%
+4 hrs · unknown
$2.53 ▼ 9.48%

The stock had already moved -5.89% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ LGVN · stock on Yahoo Finance ↗

See more from November 12, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.